Modular Medical Reports $28.2 Million Net Loss and Increased R&D Spending in Latest 10-K Filing

Modular Medical, Inc. has reported significant financial developments in its latest 10-K filing for the fiscal year ending March 31, 2026. The company, which specializes in innovative insulin pump technology, recorded a net loss of approximately $28.2 million, an increase from a loss of $18.8 million in the previous fiscal year. This reflects a year-over-year increase of 50% in losses, primarily driven by heightened research and development (R&D) expenses, which rose to $20.0 million from $14.7 million. The increase in R&D spending was attributed to higher personnel costs, consulting fees, and material expenditures related to the development of their new insulin pump product, Pivot.

In terms of operational metrics, Modular Medical has made strides in product development and regulatory approvals. The company received FDA clearance for its MODD1 insulin pump in September 2024 and subsequently for its next-generation Pivot pump in April 2026. The Pivot product, which is designed to be more user-friendly and cost-effective, was commercially launched in June 2026. The company aims to expand its market presence, targeting both Type 1 and Type 2 diabetes patients, and plans to seek regulatory approval for international markets, including obtaining the CE mark for Europe by mid-2027.

The company’s financial position remains precarious, with cash and cash equivalents decreasing to $6.9 million from $13.1 million year-over-year. This decline raises concerns about the company's ability to sustain operations without additional funding. Modular Medical has indicated that it will need to raise substantial capital to support ongoing operations and product commercialization efforts. The company completed a public offering in April 2026, generating approximately $3.0 million in net proceeds, but further financing will be necessary to cover operational costs and R&D activities.

As of March 31, 2026, Modular Medical employed 51 individuals, with a significant focus on R&D and manufacturing operations. The company has identified a target market of approximately 4.2 million potential insulin pump users in the U.S., with a significant portion classified as "Almost Pumpers," who are likely to adopt insulin pump technology if it is made more accessible and affordable. The company’s strategic focus on simplifying the user experience and reducing costs aims to capture this underserved market segment.

Looking ahead, Modular Medical anticipates continued increases in both R&D and general administrative expenses as it expands its workforce and marketing efforts. The company remains committed to enhancing its product offerings and addressing the needs of diabetes patients, but it faces substantial challenges in achieving profitability and maintaining liquidity in a competitive market. The outlook remains uncertain, with the company emphasizing the need for additional capital to support its growth initiatives and operational sustainability.